Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells

Platinum-taxane combination chemotherapy still represents the standard of care for advanced non-small cell lung cancer (NSCLC) with no targetable driver mutations. However, the efficacy of these drugs has plateaued at 10–14 months primarily due to dose-limiting toxicity, chemoresistance, and metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyakulaga, Al Hassan, Aqil, Farrukh, Munagala, Radha, Gupta, Ramesh C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185067/
https://www.ncbi.nlm.nih.gov/pubmed/32362998
http://dx.doi.org/10.18632/oncotarget.27519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185067/
https://www.ncbi.nlm.nih.gov/pubmed/32362998
http://dx.doi.org/10.18632/oncotarget.27519

Ejemplares similares